Menu
Learn More

Featured News ENZC

Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review
Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line
Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success
Enzolytics, Inc. Finalizing Regulatory Labeling Requirements for Delivery of ITV-1 Treatments for Use in Hospitals in Central and Eastern Africa – Company also Provides Additional Details on the Sale of Biogenysis and Virogentics
Enzolytics, Inc. Announces Execution of Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp. and Updates the Progress on the African Project
Enzolytics, Inc. Highlights Plans for Promotion of IPF Immune(TM), Its Patented Nutraceutical Supplement
Enzolytics to Develop Feline Monoclonal Antibodies
ENZC Quote | News | Filings
NEWSLETTER
© 2023 Stock Day Media
Financial Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Analyst Ratings by Zacks. Terms of Use.
Stock Day Media may receive direct compensation of $500 to $10,000 for content and or advertisements, that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where it contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.
X
Search
Generic filters